Platelet release protein which inhibits plasminogen activators

NUALA A BOOTH, JUDITH A ANDERSON, BRUCE BENNETT

From the Department of Medicine, University of Aberdeen, Aberdeen Royal Infirmary, Aberdeen, Scotland

SUMMARY An inhibitor of plasminogen activator has been identified in human platelets by the technique of sodium dodecyl sulphate polyacrylamide gel electrophoresis and zymography. The inhibitor has a molecular weight of about 40 000 and is distinct from known plasma protease inhibitors. It is associated almost exclusively with platelets, with only trace amounts in platelet free plasma. The inhibitor is released during platelet aggregation or in vitro coagulation. This inhibitor inhibits both tissue type plasminogen activator and urokinase but has no effect on plasmin. It forms a 1:1 complex with tissue type plasminogen activator, which retains activity detectable under the analytical conditions used. A similar complex with urokinase either forms less readily or retains less activity.

The activation of plasminogen to plasmin by plasminogen activators (PA) is central to the process of fibrinolysis, in which plasmin digests the insoluble fibrin matrix of thrombi to form soluble products. The activity of plasmin thus formed is controlled by its major plasma inhibitor, α2-antiplasmin; free plasmin in the circulation is neutralised immediately by this inhibitor.1 The existence of specific inhibitors of PA has been disputed for many years. The major reason for the controversy has been the technical difficulty of distinguishing between inhibitors of PA and inhibitors of plasmin. In the past two years evidence has been accumulating for the existence of an inhibitor of PA in plasma. The existence of this inhibitor was suggested by the finding that when low concentrations of purified tissue type PA (t-PA) were added to plasma losses of PA activity could be detected.2-4 An endothelial cell inhibitor of PA has also been described.4 This inhibitor was detected in samples separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and analysed for inhibition of PA in a fibrin/plasminogen/PA detector gel.6 The same technique was used to analyse normal human plasma for inhibitors of the fibrinolytic system, and we found that the only inhibitor specific for PA present in plasma had a molecular weight of about 40K.7 In this paper we report that this plasma inhibitor of PA is present mainly in platelets and is released from platelets by all known aggregating agents. We also report on its interactions with both t-PA and urokinase PA (u-PA).

Material and methods

BLOOD SAMPLES
Blood samples were collected into 0-1 vol of 0-13M sodium citrate. Platelet free plasma was prepared by centrifugation at 1850 g for 30 min at 4°C and platelet poor plasma was prepared by centrifugation at 1000 g for 15 min at 4°C. Serum was similarly prepared from blood, collected into glass tubes containing no anticoagulant, and incubated at 37°C for 30 min before centrifugation. Platelet rich plasma was prepared by centrifugation at 170 g for 10 min at 20°C. Platelets were prepared from platelet rich plasma by centrifugation at 1850 g for 15 min at room temperature and resuspended in 0-9% (wt/vol) aqueous sodium chloride. All plasma and serum samples were stored at −70°C.

PLATELET COUNTING
Platelets were counted in plasma samples using a Coulter Thrombocounter C.

PLATELET AGGREGATION
Platelet rich plasma was aggregated by incubation at 37°C for 5 min with adenosine diphosphate (ADP) (2-5 μM), collagen (2-5 μg/ml), ristocetin (3-0 mg/ml), or thrombin (0-5 U/ml), all final concentrations, and centrifuged at 1000 g for 15 min at 4°C.

GEL FILTRATION
The method used was based on that of Tangen.8 Platelet rich plasma (3 ml) was applied to a column of Sepharose 2B (1-6 × 30 cm) and eluted with 140

Accepted for publication 27 March 1985
mM sodium chloride, 13 mM sodium citrate at room temperature. The eluate was monitored for PA inhibitory activity by zymography, for absorbance at 280 nm and platelet count.

PLATELET LYSATES
Platelets, separated from platelet rich plasma by gel filtration, were lysed at maximum setting in a MSE ultrasonic disintegrator Model 150 W, using 3–5 s bursts with 1 min intervals.

ZYMOGRAPHIC METHODS
SDS-PAGE with zymography on fibrin-agarose layers was based on the method of Granelli-Piperno and Reich. PA activity in samples separated by SDS-PAGE was visualised on a detector gel containing fibrin and plasminogen. PA activates the plasminogen to plasmin, which lyses the opaque fibrin layer and produces clear bands of lysis. This method was adapted for detection of inhibitory activity, as described previously, by additionally incorporating into the detector gel sufficient PA (either t-PA or u-PA) to cause lysis of the entire gel in 16 h. Inhibitor bands are detectable as opaque bands of fibrin, resistant to lysis, in an otherwise clear detector gel. For both zymographic methods samples (10 µl) were prepared for SDS-PAGE by incubation with 10 µl of sample buffer (8 M urea, 4% SDS, 40 mM iodoacetamide, 0.2 M Tris, pH 8.0) for 30 min at 37°C and then made 10% with respect to glycerol. They were applied to a Laemmli gel (separating and stacking gels were 10% and 3% acrylamide respectively; gel measured 180 × 200 × 1.2 mm) and run at 20 mA for 3.5 h. The gel was washed for 1 h in 1 litre of 2.5% aqueous Triton X-100 with constant agitation and rinsed repeatedly with distilled water before it was applied to a 1.3 mm thick detector gel, which contained the following: fibrinogen (Kabi L) 2 mg/ml; plasminogen (a contaminant of the fibrinogen) 2.0–3.0 µg/ml; thrombin 0.06 U/ml; 17.5 mM sodium chloride; 60 mM Tris, pH 7.8; 0.8% agarose (all final concentrations). For detection of inhibitors the fibrin gels also contained either u-PA (Leo urokinase) 0.075 Ploug units/ml or t-PA, prepared from human heart tissue, 0.035 NIBSC units/ml. In control experiments plasmin (Kabi) 0.005 CU/ml was incorporated in the gels in place of PA plus plasminogen. After 16 h at 37°C the polyacrylamide gel was removed and the detector gel photographed.

Results
Normal platelet poor plasma, when analysed for inhibitors by SDS-PAGE plus zymography, showed two bands of inhibition at 75K and 40K molecular weight. The 75K band was identified previously as α2-antiplasmin using plasma specifically depleted of this protein by immunoabsorption. The 40K inhibitor showed variable and often weak inhibitory activity in platelet poor plasma and showed consistently stronger activity in serum than in plasma samples. Strong inhibition was seen at 40K when platelet rich plasma or washed platelet suspensions

![Fig. 1](http://jcp.bmj.com/)

Fig. 1 Analysis of samples for inhibition of urokinase mediated lysis of fibrin. Samples (10 µl) were: (a) (left to right) platelet poor plasma (platelet count 20 × 10⁶/l); platelet rich plasma (platelet count 320 × 10⁶/l); serum; platelet suspension (platelet count 150 × 10⁶/l); and (b) supernatants from incubations of platelet rich plasma with (left to right) sodium chloride (control); ADP; ristocetin; thrombin; collagen.
Platelet inhibitor of plasminogen activators

were analysed (Fig. 1a). These observations suggested that it was released from platelets during clot formation. This was tested by aggregation of platelet rich plasma with ADP, collagen, ristocetin, or thrombin. In all cases aggregation was associated with release of the inhibitor into the supernatant (Fig. 1b).

The distribution of the 40K inhibitor in blood was examined by gel filtration of platelet rich plasma on Sepharose 2B. More than 95% of this inhibitor was associated with the platelet fraction, with only a trace in the plasma protein peak, in which α2-antiplasmin was easily detected (Fig. 2a). When the same platelet rich plasma was aggregated before gel filtration and the corresponding fractions analysed the 40K inhibitor, released on aggregation, was present in the protein peak (Fig. 2b).

The specificity of the 40K inhibitor for PA was examined by comparing the inhibition found in platelets and plasma when the detector gel was lysed by u-PA plus plasminogen, t-PA plus plasminogen, or preformed plasmin. Inhibition of u-PA or t-PA mediated lysis was seen at 40K, although inhibition of t-PA was apparently weak in this system (Fig. 3). In contrast, the 40K protein had no inhibitory effect when the detector gel was lysed by preformed plasmin; only α2-antiplasmin was inhibitory under these conditions. The difference in molecular size between the inhibitor band in plasma and in plasma free platelet suspensions is due to the high protein concentrations in the plasma samples, which causes dragging of the bands in these samples.12

Purified t-PA or u-PA was incubated with increasing concentrations of sonicated, gel filtered platelets for 5 min at 37°C and these mixtures were analysed for PA activity by SDS-PAGE and zymography. Even at low concentrations of sonicated platelets an additional band of t-PA related activity was seen at about 110K (Fig. 4), consistent with formation of a 1:1 complex between t-PA (65K) and the 40K

Fig. 2. (a) Platelet rich plasma (3 ml) was separated on Sepharose 2B (1.6 x 30 cm). (b) The same sample of platelet rich plasma was aggregated with 0.5 U/ml of thrombin before gel filtration. The gels show analysis of the platelet and protein peaks for inhibition of urokinase mediated lysis of fibrin.
platelet inhibitor. No evidence for complex formation between u-PA and the inhibitor was found (Fig. 4) except where the concentration of platelet lysate was greatly increased and an extremely faint band of high molecular weight activity was just visible (not illustrated). These data are consistent either with relatively poor formation of a complex between u-PA and the platelet inhibitor or low activity of such a complex in the analytical system used.

Discussion

We have shown that the 40K inhibitor of PA, detectable in plasma by a zymographic technique,7 is a platelet protein. The presence of low and variable inhibitory activity at 40K in platelet poor plasma probably reflects variation in numbers of contaminating platelets. In this system platelets in the sample are lysed during incubation in the SDS buffer; prior disruption is not required. Variable detection of this inhibitor in plasma may also reflect variable in vitro platelet release of inhibitor; careful collection and processing of plasma samples is essential to avoid in vitro release reactions which may artificially raise "plasma" concentrations of this inhibitor.

The platelet inhibitor is effective towards both t-PA and u-PA. In this system the inhibition of u-PA is apparently stronger than that of t-PA; possible explanations for this have already been proposed.7 Complex formation between t-PA and the platelet inhibitor has been shown in this study. This complex retains some PA activity as has been noted previously for other protease inhibitor complexes.11 The complex is of the same molecular weight as the t-PA complex which is present in normal plasma.12 Thus this platelet inhibitor may have a role in the regulation of normal t-PA activity in the circulation. It is interesting that a complex between u-PA and this inhibitor either occurs less readily or is less active in the zymographic system. This is consistent with the situation in resting normal plasma, where u-PA activity is present at 50K, the molecular weight of free u-PA, while the t-PA activity is present at 110K, suggesting its presence as a complex. Even in the plasma of patients with alcoholic cirrhosis, where both t-PA and u-PA are increased, only free u-PA activity is detectable, while t-PA is present in both free and complexed forms.13

The relationship between this inhibitor and other inhibitors of t-PA and u-PA is not yet established. In studies reported elsewhere we have shown that it differs immunologically from the major known protease inhibitors of plasma.7 Plasma inhibitors described as "fast antiactivator" and "fast-acting t-PA inhibitor" have been described recently.2-4 It is of interest that the plasma concentrations of these inhibitors are widely variable in a normal population,2-14 which, our observations suggest, could be interpreted as reflecting variable platelet contamination or release, or both, if the inhibitors detected in this and other studies are identical. The different methods used may be sensitive to different types of inhibition; however, as has been suggested for the

Fig. 3 Analysis of inhibition of fibrin lysis, when the detector gel was lysed by (a) urokinase; (b) tissue type plasminogen activator, or (c) plasmin. Samples in all three groups were (left to right): 5 μl of platelet poor plasma (platelet count 20 X 10⁹/l); 5 μl of platelet poor plasma plus 5 μl of platelet suspension (platelet count 120 X 10⁹/l); 5 μl of platelet suspension.
Platelet inhibitor of plasminogen activators

inhibitors present in endothelial cell conditioned medium. Verheijen and colleagues have described an inhibitor of t-PA in plasma which, they conclude, is not derived from platelets, and the plasma inhibitor found by Wiman's group is of much higher molecular weight than that described here. The presence in platelets of an inhibitor of PA has also been shown recently by Erickson and colleagues by the same method as that used here. Inconsistencies between their results and ours may be explained by technical differences. For instance, they did not detect inhibition at 75K in plasma or serum samples, though this inhibitor was consistently detected in our studies and identified as being due to α2-antiplasmin. While the concentration of u-PA in the detector gel is similar in the two laboratories, the time taken for complete lysis is strikingly different (16 h vs 2 h), probably reflecting the difference in plasminogen concentration (2.5 μg/ml vs 25 μg/ml). This may explain differences in sensitivity between the two studies.

A number of recent reports on inhibitors of PA from endothelial cells indicate the similarity between the platelet and endothelial cell inhibitors. Erickson et al have shown the immunological relation between them. Other workers have noted the formation of a complex between the endothelial cell inhibitor and PA, similar in molecular weight to the complex we report here for the platelet inhibitor.

Although most of these inhibitors have been studied mainly in terms of their effects on t-PA, some of them also inhibit u-PA. Clearly, comparative studies are required to establish the identities or otherwise of all these recently described inhibitors in respect of their immunology, cellular origin, and the nature of their molecular interactions with t-PA and u-PA.

Fig. 4 Analysis of samples for plasminogen activator activity (PA). Samples were incubated at 37°C for 5 min before addition of sample buffer and contained: (a) urokinase (u-PA) 0.1 Ploug unit; (b) u-PA 0.1 Ploug unit plus 2 x 10⁶ lysed gel filtered platelets; (c) u-PA 0.1 Ploug unit plus 100 x 10⁶ lysed gel filtered platelets; (d) tissue type plasminogen activator (t-PA) 0.01 NIBSC unit; (e) t-PA 0.01 NIBSC unit plus 2 x 10⁶ lysed gel filtered platelets; (f) t-PA 0.01 NIBSC unit plus 100 x 10⁶ lysed gel filtered platelets; (g) 100 x 10⁶ lysed gel filtered platelets.
This study was supported by the Medical Research Council and the Scottish Home and Health Department. We thank Mrs Susan Beattie for excellent technical assistance and Mr John McIntosh of the Department of Medical Illustration for skilful photographic work.

References

19 van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. *J Biol Chem* 1984;259:14914–21.

Requests for reprints to: Dr Nuala A Booth, Department of Medicine, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB9 2ZB, Scotland.
Platelet release protein which inhibits plasminogen activators.

N A Booth, J A Anderson and B Bennett

_J Clin Pathol_ 1985 38: 825-830
doi: 10.1136/jcp.38.7.825

Updated information and services can be found at:
_http://jcp.bmj.com/content/38/7/825_

**Email alerting service**

_These include:_

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
_http://group.bmj.com/group/rights-licensing/permissions_

To order reprints go to:
_http://journals.bmj.com/cgi/reprintform_

To subscribe to BMJ go to:
_http://group.bmj.com/subscribe/_